Recruiting

Transvesical Prostatectomy vs. HIFUSingle-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

Sponsor:

Case Comprehensive Cancer Center

Code:

NCT05610852

Conditions

Prostate Adenocarcinoma

Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 19+

Healthy Volunteers: Not accepted

Interventions

Transvesical Single Port Robotic Partial Prostatectomy

High-intensity focused ultrasound (HIFU)

Study Details

Brief summary:

This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.

Conditions

Prostate Adenocarcinoma

Prostate Cancer

Study ID

NCT05610852

Start date

Jan 1, 2024

Status verified date

Aug, 2026

Completion date

Dec 1, 2028

Anticipated

Primary completion date

Dec 1, 2026

Anticipated

Eligibility Criteria

Sex: Male

Age: 19+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Subjects must have histologically or cytologically: Biopsy-confirmed prostate cancer, stage T1a, T2a, T2b, or T2c prostate cancer using MRI staging, with a region of interest (ROI) PIRADs grade 3 or greater, Serum PSA 10 ng/ml or less, Region of interest on MRI of grade 3 or greater
The MRI performed must include at least:
A T2-weighted sequence in sections ≤ 4 mm, centered on the prostate and seminal vesicles, at least in the axial plane. Alternatively, a 3D T2-weighted sequence can be realized,
A diffusion sequence of ≤ 4 mm slice in the axial plane. An ADC card will be provided and calculated from at least two values of b, the maximum value of b being ≥ 600 s / mm2,
A dynamic sequence after gadolinium injection. It will be a sequence of echo T1-weighted gradient of slice ≤ 4 mm, centered on the prostate and seminal vesicles in the axial plane, with or without fat saturation. A first series will be performed without contrast injection, and will be repeated iteratively for the arrival of a bolus of gadolinium chelates. The time resolution (that is to say, the acquisition time of one dynamic series will be ≤ 20 seconds). The number of chained dynamic series is calculated so that the total length of the dynamic acquisition be at least 3 minutes
A total dose of 0.1 mmol / kg of gadolinium chelate will be injected at a rate of 3-4 mL / s by using an automatic injector, in a vein of the hand of the forearm or elbow.
If necessary, subtracted images are calculated
Clinically significant prostate cancer defined as Gleason score 3+4 or less in any core
Biopsies for preoperative diagnosis of prostate cancer will have included: At least 12 randomized samples (2 samples per sextant), At least two targeted sampling on each target score MRI ESUR ≥ 3/5
Life expectancy greater than 10 years.
Age >18 years.
Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Patients with any prior extensive pelvic surgery, pelvic fractures, hemorrhoid, fissure surgery, cardiac pacemaker, or metal prosthesis
Prior treatment for prostate cancer such as radiotherapy, focal or hormonal therapy
Uncorrected coagulopathy or history of Latex allergy
Active soft tissue or urinary infection, indwelling Foley catheter or severe irritative or obstructive symptoms
Poor surgical risk (defined as American Society of Anesthesiology score > 3).
Any condition or history of illness or surgery that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient (e.g. significant cardiovascular conditions that significantly affect the life expectancy, chronic opiate use, pain syndrome, or drug abuse.)
Prostate size larger than 80 grams.
Subjects with prostatic Calcification (>0.5 cc) close to the area to be treated.
Subjects with extraprostatic extension or cribriform pattern on biopsy.
Subjectes with sexual dysfunction defined as SHIM score < 17
Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Study Design

Enrollment

276 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Transvesical Single Port Robotic Partial Prostatectomy

Participants will have a multiparametric prostate MRI and diagnostic prostate biopsy with confirmed localized prostate tumor prior to Prostatectomy. Prostatectomy consists of a single treatment. All participants will have a postoperative visit at 3 days after surgery, followed by phone calls at 1 week, 2 weeks and 4 weeks, followed by office visits at 6 weeks, 3 months, 6 months, 9 months, 1 year, 2 years and 3 years. Participants will be followed indefinitely as per standard of care.

active comparator: High-intensity focused ultrasound (HIFU)

Participants will have a multiparametric prostate MRI and diagnostic prostate biopsy with confirmed localized prostate tumor prior to HIFU. HIFU consists of a single treatment. All participants will have a postoperative visit at 3 days after surgery, followed by phone calls at 1 week, 2 weeks and 4 weeks, followed by office visits at 6 weeks, 3 months, 6 months, 9 months, 1 year, 2 years and 3 years. Participants will be followed indefinitely as per standard of care.

Interventions

Transvesical Single Port Robotic Partial Prostatectomy

A foley catheter is inserted on the sterile field. A suprapubic midline incision is made and the da Vinci SP surgical system is docked percutaneously directly to the bladder. Prior to the operation, a radiologist identifies and segments tumors and the urethra. A transrectal ultrasound probe is inserted and secured into a fixed position. The Koelis software is utilized to fuse MRI and ultrasound images to identify the target lesion in real-time, allowing for intraoperative guidance. The ultrasound probe rotates automatically, allowing for localization of the tumor intraoperatively. Then depending on the area of the tumor, a Hemi or quadrant resection is completed while preserving the nerves, vas deferens, and seminal vesicles. The urethrovesical anastomosis is then performed.

High-intensity focused ultrasound (HIFU)

Three contoured measurements are required for the MR fusion system to reproduce the volume of the prostate. Following this, the area to be targeted will be selected in graded fashion from the anterior to posterior of the prostate. Once planning of ROI (region of interest) is complete, the HIFU treatment may begin. Quadrant or hemi ablation will be performed based on the size and complexity of the tumor. The distal margin of the ablation will be kept at least 4 mm away from the external sphincter. The rectal temperature and its distance from the probe will be carefully monitored throughout the procedure.

Primary outcome measure

Recurrence free survival Recurrence free survival [ Time Frame: 1 year after treatment ]
Recurrence free survival [ Time Frame: 2 years after treatment ]
Recurrence free survival [ Time Frame: 3 years after treatment ]

Central Contacts and Locations

Central contacts

Jihad Kaouk, MD

216-444-2976 kaoukj@ccf.org

Locations

Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center

Recruiting

Cleveland, Ohio, United States, 44195

Contacts

Jihad Kaouk, MD

kaoukj@ccf.org

More Information

Sponsor

Case Comprehensive Cancer Center

Last update posted

Aug 6, 2026

Last verified

Aug, 2026

Keywords

High Intensity Focused Ultrasound (HIFU)
Single-Port Transvesical Partial Prostatectomy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Case Comprehensive Cancer Center on 2026-08-06.